Lawrence J. Hineline - 14 Jun 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
SVP of Finance CFO
Signature
/s/ Lawrence J. Hineline
Issuer symbol
ITCI
Transactions as of
14 Jun 2023
Net transactions value
-$1,774,012
Form type
4
Filing time
16 Jun 2023, 17:05:14 UTC
Previous filing
13 Mar 2023
Next filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $2,170,513 +40,472 $53.63 40,472 14 Jun 2023 Direct
transaction ITCI Common Stock Options Exercise $600,463 +25,082 +62% $23.94 65,554 14 Jun 2023 Direct
transaction ITCI Common Stock Options Exercise $433,900 +11,762 +18% $36.89 77,316 14 Jun 2023 Direct
transaction ITCI Common Stock Options Exercise $257,441 +4,538 +5.9% $56.73 81,854 14 Jun 2023 Direct
transaction ITCI Common Stock Sale $2,168,280 -34,227 -42% $63.35 47,627 14 Jun 2023 Direct F1, F2
transaction ITCI Common Stock Sale $2,834,533 -44,035 -92% $64.37 3,592 14 Jun 2023 Direct F1, F3
transaction ITCI Common Stock Sale $233,516 -3,592 -100% $65.01 0 14 Jun 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to purchase) Options Exercise $0 -40,472 -100% $0.000000* 0 14 Jun 2023 Common Stock 40,472 $53.63 Direct F5
transaction ITCI Stock Option (right to purchase) Options Exercise $0 -25,082 -100% $0.000000* 0 14 Jun 2023 Common Stock 25,082 $23.94 Direct F5
transaction ITCI Stock Option (right to purchase) Options Exercise $0 -11,762 -67% $0.000000 5,882 14 Jun 2023 Common Stock 11,762 $36.89 Direct F6
transaction ITCI Stock Option (right to purchase) Options Exercise $0 -4,538 -33% $0.000000 9,078 14 Jun 2023 Common Stock 4,538 $56.73 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.795 to $63.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.79 to $64.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.81 to $65.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 All shares underlying this option have vested.
F6 On February 23, 2021, the reporting person was granted options to purchase 17,644 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
F7 On March 10, 2022, the reporting person was granted options to purchase 13,616 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.